AgingNCT07406243
Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women
A study testing Mitoquinone (MitoQ) in people with Aging and Postmenopause, run by Colorado State University at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ [a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal… Read more about this study
- Who is it for?
- Ages 60 years and older, women only
- Conditions the study is for
- Aging, Postmenopause
- What is being tested?
- Mitoquinone (MitoQ)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 86 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2026to Jul 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 60 years or older;
- Postmenopausal women defined as at least 1 year without menses as self-reported;
- Estrogen-deficient; no hormone therapies (e.g., estrogen, progesterone, testosterone, DHEA, oral contraceptives, etc.) within the previous 6 months;
- Ability to provide informed consent;
- Willing to accept random assignment to condition;
- Body mass index (BMI) ≤35 kg/m2;
Show all 10Show fewer
- Mini-mental state examination score ≥21;
- Weight stable in the prior 3 months;
- Abstinence from antioxidant or CoQ10 therapy for 3 months; and
- Absence of clinical disease as determined by the physician of record following a medical history and blood chemistries
Who cannot join
- History of uncontrolled hypertension;
- Currently meeting aerobic exercise guidelines of ≥75 mins/week of vigorous or ≥150 mins/week of moderate intensity exercise as assessed by Modified Activity Questionnaire;
- Current smoker;
- Alcohol dependence or abuse;
- Other chronic medical conditions; and
- Subject report of blood donation within 8 weeks prior to enrolling.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Translational Physiology Laboratory within the Food Science Clinical Research Laboratory
Fort Collins, Colorado, 80526
Kevin Murray, PhD, (970) 491-3663, fshn_tpl@colostate.edu
Kevin Murray, PhD
About this study
Official title: Mitochondrial-Targeted Antioxidant Supplementation for Improving Cerebrovascular Function in Postmenopausal Women
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ [a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are:
Does MitoQ improve cerebrovascular function in postmenopausal women?
Read more
If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries?
Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function.
Participants will:
Take MitoQ (20 mg/day) or a placebo every day for 3 months
Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point
Keep track of symptoms and events during their treatment period to report to the study team
- Conditions
- Aging, Postmenopause
- Being tested
- Mitoquinone (MitoQ), Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mitoquinone (MitoQ)Dietary supplement
MitoQ is a biochemically modified form of ubiquinol
Other Names:
Mitoquinol
PlaceboDietary supplement
Each placebo capsule contains inert excipient and is identical in appearance
| Study group | Role | What they receive |
|---|---|---|
| MitoQ, 20 mg/day | Experimental | Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months. Receives: Dietary Supplement: Mitoquinone (MitoQ) |
| Placebo | Placebo comparator | Matched placebo capsules. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in cerebrovascular conductance at 3 months
Middle cerebral artery blood velocity in response to hypercapnia normalized for changes in end-tidal carbon dioxide and blood pressure
Measured: 3 months
Secondary outcomes (9)
Change from baseline in cerebrovascular reactivity at 3 months
Middle cerebral artery blood velocity in response to hypercapnia normalized to changes in end-tidal carbon dioxide
Measured: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of cerebrovascular conductance at 3 months
Cerebrovascular conductance to hypercapnia following administration of a supratherapeutic dose of MitoQ (160 mg) known to scavenge mitochondrial reactive oxygen species
Measured: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of cerebrovascular reactivity at 3 months
Cerebrovascular reactviity to hypercapnia following administration of a supratherapeutic dose of MitoQ (160 mg) known to scavenge mitochondrial reactive oxygen species
Measured: 3 months
Change from baseline in internal carotid artery dilation in response to hypercapnia at 3 months
Cerebrovascular endothelium-dependent dilation
Measured: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of internal carotid artery dilation at 3 months
Internal carotid artery dilation to hypercapnia following administration of a supratherapeutic dose of MitoQ (160 mg) known to scavenge mitochondrial reactive oxygen species
Measured: 3 months
Change from baseline in total cerebral blood flow at 3 months
The amount of blood flow feeding the brain at rest
Measured: 3 months
Change from baseline in cerebrovascular stiffness at 3 months
Resting middle cerebral artery pulsatility index
Measured: 3 months
Change from baseline in carotid artery compliance at 3 months
Change in diameter of carotid artery for a given change in pressure
Measured: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of carotid artery compliance at 3 months
Carotid artery compliance following administration of a supratherapeutic dose of MitoQ (160 mg) known to scavenge mitochondrial reactive oxygen specie
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2026
- Study startApr 2026 (estimated)
- Primary completionJan 2030 (estimated)
- Study completionJul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Colorado State University
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07406243
- Sponsor's protocol ID
- 7559
- Other IDs
- K01HL177339
- Status last verified
- Feb 2026
- First submitted
- 6 Feb 2026
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The IPD will not be on a publicly available repository, however, any or all data may be made available upon reasonable request and collaboration.
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mitochondrial-Targeted Antioxidant Supplementation for Improving Cerebrovascular Function in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT07406243
- Acronym / sponsor ID
- 7559
- Conditions
- Aging, Postmenopause
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- Colorado State UniversityUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Apr 2026 (estimated)
- Primary completion
- Jan 2030 (estimated)
- Study completion
- Jul 2030 (estimated)
- First posted
- 12 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ [a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are:
Does MitoQ improve cerebrovascular function in postmenopausal women?
If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries?
Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function.
Participants will:
Take MitoQ (20 mg/day) or a placebo every day for 3 months
Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point
Keep track of symptoms and events during their treatment period to report to the study team
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MitoQ, 20 mg/day | Experimental | Dietary Supplement: Mitoquinone (MitoQ)Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboMatched placebo capsules. |
Who may qualify
- Ages
- 60 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age 60 years or older;
- Postmenopausal women defined as at least 1 year without menses as self-reported;
- Estrogen-deficient; no hormone therapies (e.g., estrogen, progesterone, testosterone, DHEA, oral contraceptives, etc.) within the previous 6 months;
- Ability to provide informed consent;
- Willing to accept random assignment to condition;
Key exclusion criteria (6 listed)
- History of uncontrolled hypertension;
- Currently meeting aerobic exercise guidelines of ≥75 mins/week of vigorous or ≥150 mins/week of moderate intensity exercise as assessed by Modified Activity Questionnaire;
- Current smoker;
- Alcohol dependence or abuse;
- Other chronic medical conditions; and
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mitoquinone (MitoQ)MitoQ is a biochemically modified form of ubiquinol Other Names: Mitoquinol | Dietary supplement | MitoQ, 20 mg/day |
| PlaceboEach placebo capsule contains inert excipient and is identical in appearance | Dietary supplement | Placebo |
Primary outcome
Change from baseline in cerebrovascular conductance at 3 months
Time frame: 3 months
Middle cerebral artery blood velocity in response to hypercapnia normalized for changes in end-tidal carbon dioxide and blood pressure
9 secondary outcomes
Change from baseline in cerebrovascular reactivity at 3 months
Time frame: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of cerebrovascular conductance at 3 months
Time frame: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of cerebrovascular reactivity at 3 months
Time frame: 3 months
Change from baseline in internal carotid artery dilation in response to hypercapnia at 3 months
Time frame: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of internal carotid artery dilation at 3 months
Time frame: 3 months
Change from baseline in total cerebral blood flow at 3 months
Time frame: 3 months
Change from baseline in cerebrovascular stiffness at 3 months
Time frame: 3 months
Change from baseline in carotid artery compliance at 3 months
Time frame: 3 months
Change from baseline in mitochondrial oxidative stress-mediated suppression of carotid artery compliance at 3 months
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: Yes. The IPD will not be on a publicly available repository, however, any or all data may be made available upon reasonable request and collaboration.
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mitoquinone (MitoQ) in people with Aging and Postmenopause, run by Colorado State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kevin Murray, PhD ((970) 491-3663, fshn_tpl@colostate.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in cerebrovascular conductance at 3 months (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.